Ultimately, the negative results of the JACOB trial, which evaluated the efficacy of dual-HER2 therapy and chemotherapy in advanced GC/GEJC, led to a premature termination of the PETRARCA trial [102]. This evidence concerns the gene ERBB2 and gastric cancer.